[ad_1]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount. Enveric plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-
[ad_2]
Source link
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
-
PreviousQuolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases
-
NextPESG Industry Updates: Germany’s Cannabis Act and Its Impact on the Medical Cannabis Landscape
